Seres Therapeutics Inc (NASDAQ:MCRB) shares, rose in value, with the stock price up by 1.81% to the previous day’s close as strong demand from buyers drove the stock to $0.74.
Actively observing the price movement in the last trading, the stock closed the session at $0.73. Referring to stock’s 52-week performance, its high was $6.73, and the low was $0.54. On the whole, MCRB has fluctuated by -1.24% over the past month.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 250k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that MCRB’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MCRB currently trading nearly 6.59% and -13.36% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.91, while the 7-day volatility ratio is showing 16.12% which for the 30-day chart, stands at 9.35%. Furthermore, Seres Therapeutics Inc (MCRB)’s beta value is 2.25, and its average true range (ATR) is 0.07.
A comparison of Seres Therapeutics Inc (MCRB) with its peers suggests the former has fared considerably weaker in the market. MCRB showed an intraday change of 1.81% in last session, and over the past year, it shrunk by -87.94%%.
Data on historical trading for Seres Therapeutics Inc (NASDAQ:MCRB) indicates that the trading volumes over the past 3 months, they’ve averaged 4.07 million. According to company’s latest data on outstanding shares, there are 135.04 million shares outstanding.
Nearly 20.91% of Seres Therapeutics Inc’s shares belong to company insiders and institutional investors own 44.24% of the company’s shares. The stock has fallen by -46.95% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MCRB stock heading into the next quarter.
